dormorna glp 1 GLP-1 Microdosing – Kora MD and intra GLP-1 Support - 6 Month
Description
This will eventually include Medicare [as well as commercial players], where we see coverage by the end of the decade based on the expected strength of these datasets. As with diabetes, JPM also sees the obesity market to be a $50 billion one by 2030 and largely a duopoly between Lilly and Novo
GrosseJHeffronHBurlingKHossainMAHabibAMRogersGJet al
Frontiers in Endocrinology, 16, 1593334
A randomized, placebo-controlled, double-blind, crossover trial was conducted in 42 patients with type 2 diabetes
